| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | CSAID Binding protein 1, CSBP1, CSBP2, EXIP, MAP kinase MXI2, MAPkinase p38alpha, MAPK14, p38 ALPHA, p38 MAP kinase, p38 mitogen activated protein kinase, RK, SAPK 2A, Stress activated protein kinase 2A |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Full length recombinant protein expressed in E.coli cells |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
p38 MAPK (also known as SAPK2α) is a stress-activated kinase that orchestrates cellular responses to inflammatory and oxidative stimuli. It is activated by phosphorylation in response to diverse stressors, including hydrogen peroxide, cytokines, UV light, and chemotherapeutic agents.
In neurons, p38 MAPK regulates apoptosis, synaptic remodeling, and inflammatory gene expression. Its activation leads to mitochondrial cytochrome c release and caspase-3 activation, contributing to neurodegeneration. Elevated p38 MAPK activity has been observed in Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
Given its central role in stress signaling and cell death, p38 MAPK is a validated target for therapeutic intervention in neurodegenerative and inflammatory CNS disorders.
Detects ~38kDa protein corresponding to p38α MAPK when loaded with 6 ng of purified p38α by chemiluminescent immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-152D — Size: 100 ug: p38 alpha MAPK Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D, RRID: AB_2141876)
- SMC-152D-A390 — Size: 100 ug: p38 alpha MAPK Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-A390, RRID: AB_2698432)
- SMC-152D-A488 — Size: 100 ug: p38 alpha MAPK Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-A488, RRID: AB_2698433)
- SMC-152D-A594 — Size: 100 ug: p38 alpha MAPK Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-A594, RRID: AB_2698435)
- SMC-152D-APC — Size: 100 ug: p38 alpha MAPK Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-APC, RRID: AB_2698441)
- SMC-152D-BI — Size: 100 ug: p38 alpha MAPK Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-BI, RRID: AB_2698442)
- SMC-152D-FITC — Size: 100 ug: p38 alpha MAPK Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-FITC, RRID: AB_2698443)
- SMC-152D-HRP — Size: 100 ug: p38 alpha MAPK Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-HRP, RRID: AB_2698444)
- SMC-152D-PCP — Size: 100 ug: p38 alpha MAPK Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-PCP, RRID: AB_2698446)
- SMC-152D-RPE — Size: 100 ug: p38 alpha MAPK Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152D-RPE, RRID: AB_2698447)
- SMC-152S — Size: 12 ug: p38 alpha MAPK Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-152S, RRID: AB_2141876)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Fan, Y. et al (2007) Mol. Cells 23 (1): 30-38.
3. Han, J. et al. (1994) Science 265: 808-811.
4. Van, L. A., et al. (2004) Faseb J. 18: 1946−1948.
5. Deng et al. (2003) Cell. 115: 61-70.
6. Salojin KV, et al. (2006) J Immunol. 176 (3):1899-907.
7. Medicherla S. et al. (2006). J Pharmacol Exp Ther.318(1): 99-107.